Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LaFleur Advancing Restart of Beacon Gold Mill and Bulk Sample for Swanson Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Awakn Life Sciences Corp C.AWKN

Healthcare Psychedelics
Awakn Life Sciences Corp. is a Canada-based clinical-stage biotechnology company. The Company is developing therapeutics for substance use and mental health disorders, with a near-term focus on alcohol use disorder (AUD). The Company's therapeutics are focused on the brain circuits that drive addiction. The Company operates through three segments: development, delivery and corporate. The development segment, which focuses on researching and developing psychedelic drugs and therapies, ketamine-assisted psychotherapy and methylenedioxy-methamphetamine (MDMA)-assisted psychotherapy to treat substance and behavioral addictions. The delivery segment, which includes a chain of medical psychedelic clinics across Europe and through licensing partners. The Company operates in Ireland and Canada. The Company’s development pipeline includes AWKN-001, AWKN-002, MDMA Zydis, and Aminoindane new chemical entities (NCEs).


CSE:AWKN - Post by User

Awakn Life Sciences Corp
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(243)
•••
  • TheBridgeX
Post by TheBridgeon Feb 04, 2025 2:07pm
77 Views
Post# 36436938

Update Again

Update AgainJust in case you're interested. In a January 14, 2025 announcement Graft Polymer became Solvonis Therapeutics, saying that the change reflects it's growing focus on developing innovative treatments for mental health and substance use disorders. New website will be, www.solvonis.com.
CEO is Anthony Tennyson. The switch will officially take effect on January 15, 2025 and will include a new ticker symbol, SVNS.
In a January 27th. announcement Solvonis Therapeutics PLC updated investors on the research and development (R&D) advancements at Awakin Life Sciences Corp, the biotechnology it intends to acquire. Awakin is advancing three programmes focused on addressing mental health and addiction disorders.

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities